Cancer Causes & Control最新文献_第7页

Risk of bladder cancer in patients with type 2 diabetes mellitus: a retrospective population-based cohort study in Lithuania. 2 型糖尿病患者罹患膀胱癌的风险：立陶宛一项基于人群的回顾性队列研究。

IF 2.2 4区医学

Cancer Causes & Control Pub Date : 2025-01-01 Epub Date: 2024-09-21 DOI: 10.1007/s10552-024-01911-2

Adomas Ladukas, Ausvydas Patasius, Marius Kincius, Mingaile Drevinskaite, Justinas Jonusas, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, Giedre Smailyte

{"title":"Risk of bladder cancer in patients with type 2 diabetes mellitus: a retrospective population-based cohort study in Lithuania.","authors":"Adomas Ladukas, Ausvydas Patasius, Marius Kincius, Mingaile Drevinskaite, Justinas Jonusas, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, Giedre Smailyte","doi":"10.1007/s10552-024-01911-2","DOIUrl":"10.1007/s10552-024-01911-2","url":null,"abstract":"Purpose: The objective of our study was to evaluate bladder cancer risk among Lithuanian type 2 diabetes mellitus (T2DM) patients and the effect of antihyperglycemic therapy on bladder cancer risk.Methods: We analyzed bladder cancer risk in a cohort of patients who were diagnosed with T2DM between 2001 and 2012 in Lithuania. Bladder cancer risk in four groups of antihyperglycemic medication users (insulin-only, metformin-only, sulfonylurea-only, and pioglitazone ± any other drug) was also assessed. Standardized incidence ratios for bladder cancer were calculated.Results: A total of 76,818 patients (28,762 males and 48,056 females) with T2DM were included in the final cohort. In the whole cohort of diabetic patients, 277 bladder cancer cases were observed, compared to 232.75 expected cases, according to bladder cancer rates in the general population (Standardized Incidence Ratio 1.19; 95% Confidence Interval: 1.06-1.34). Higher risk of bladder cancer was found in both men and women; however, in women the risk increase was not statistically significant. We found higher risk of bladder cancer in patients of both sexes diagnosed with T2DM at the age of 50-79 years and also in all groups of different antihyperglycemic medication users.Conclusion: T2DM was associated with increased risk of bladder cancer.","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"21-25"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11761827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and concordance of penile, anal, and oral human papillomavirus infections among sexually active heterosexual men in Ibadan, Nigeria. 尼日利亚伊巴丹性活跃异性恋男性阴茎、肛门和口腔人类乳头瘤病毒感染的流行率和一致性。

IF 2.2 4区医学

Cancer Causes & Control Pub Date : 2025-01-01 Epub Date: 2024-10-03 DOI: 10.1007/s10552-024-01920-1

Imran O Morhason-Bello, Kathy Baisley, Miquel Angel Pavon, Isaac F Adewole, Rasheed Bakare, Sikiru A Adebayo, Silvia de Sanjosé, Suzanna C Francis, Deborah Watson-Jones

{"title":"Prevalence and concordance of penile, anal, and oral human papillomavirus infections among sexually active heterosexual men in Ibadan, Nigeria.","authors":"Imran O Morhason-Bello, Kathy Baisley, Miquel Angel Pavon, Isaac F Adewole, Rasheed Bakare, Sikiru A Adebayo, Silvia de Sanjosé, Suzanna C Francis, Deborah Watson-Jones","doi":"10.1007/s10552-024-01920-1","DOIUrl":"10.1007/s10552-024-01920-1","url":null,"abstract":"Background: The data on epidemiology of Human papillomavirus (HPV) infections in men are scarce relative to women generally, particularly among men engaging in heterosexual relationships. This study investigated the prevalence and risk factors for penile, anal, and oral HPV in men in two communities in Ibadan, Nigeria.Methods: This was a cross-sectional survey involving a face-to-face interview, a clinical examination, and sample collection from participants. HPV genotyping was performed with Anyplex II 28 HPV assay. The prevalences and factors associated with HPV infections using multivariable models and concordance between sites.Results: Of 316 men, the proportion of any HPV infection in the penile, anal, and oral sites was 40.5%, 9.7%, and 7.8%, respectively. The proportion of any high-risk HPV, low-risk HPV, and multiple HPV infections was highest in the penis followed by the anal and oral sites. Only 5/316 (1.6%) men had concordant HPV in all three sites, with the highest concordance in penile-anal sites relative to penile-oral and anal-oral sites. The odds of penile HPV were higher in men aged 25 years and above. Having penile HPV was associated with higher odds of detecting anal HPV and vice versa. Oral HPV was less likely in men not living with their sexual partners.Conclusion: Penile HPV is the most common infection followed by anal HPV and oral HPV infections among heterosexual Nigerian men. Concordant HPV infections was highest in penile-anal sites. Nigerian men, as in other settings, are a reservoir of HPV and it is important to conduct more robust studies to appreciate their role in HPV transmission, epidemiology, and prevention.","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"51-66"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physical activity before and after cancer diagnosis and mortality risk in three large prospective cohorts. 三个大型前瞻性队列中癌症诊断前后的体育锻炼与死亡风险。

IF 2.2 4区医学

Cancer Causes & Control Pub Date : 2025-01-01 Epub Date: 2024-10-08 DOI: 10.1007/s10552-024-01925-w

Cami N Christopher, Paulette D Chandler, Xuehong Zhang, Deirdre K Tobias, Aditi Hazra, J Michael Gaziano, Julie E Buring, I-Min Lee, Howard D Sesso

{"title":"Physical activity before and after cancer diagnosis and mortality risk in three large prospective cohorts.","authors":"Cami N Christopher, Paulette D Chandler, Xuehong Zhang, Deirdre K Tobias, Aditi Hazra, J Michael Gaziano, Julie E Buring, I-Min Lee, Howard D Sesso","doi":"10.1007/s10552-024-01925-w","DOIUrl":"10.1007/s10552-024-01925-w","url":null,"abstract":"Purpose: Physical activity (PA) can improve cancer survival; however, whether the timing of PA differentially affects mortality risk is unclear. We evaluated the association between PA levels pre- and post-diagnosis and mortality risk in the Women's Health Study (WHS), Physicians' Health Study (PHS)-I, and PHS-II prospective cohorts.Methods: We categorized PA pre- and post-diagnosis as active (WHS: ≥ 7.5 metabolic equivalent (MET)-h/week; PHS: vigorous PA ≥ 2-4 times/week) or inactive. We analyzed changes in pre- and post-diagnosis PA levels as four joint categories: (1) Inactive → Inactive, (2) Active → Inactive, (3) Inactive → Active, and (4) Active → Active, on mortality risk using multivariable Cox proportional hazards regression.Results: We identified 10,541 participants with incident cancer and 3,696 deaths during follow-up. Compared to maintaining inactivity in both periods, remaining active pre- and post-diagnosis observed lower all-cause (Hazard Ratio [95% confidence interval]: WHS: 0.55 [0.47-0.64]; PHS-I: 0.77 [0.67-0.88]), cancer (WHS: 0.55 [0.45-0.67]; PHS-I: 0.75; [0.61-0.92]) and non-cancer/cardiovascular disease (CVD) mortality risks (WHS: 0.49 [0.38-0.65]). Similarly, becoming active post-diagnosis was associated with lower all-cause (WHS: 0.60 (0.48-0.75]; PHS-I: 0.72 [0.61-0.88]), cancer (WHS: 0.65 [0.49-0.86]; PHS-I: 0.64 [0.49-0.84]), and non-cancer/CVD mortality risk (WHS: 0.49 [0.33-0.75]). Being active pre- and post-diagnosis was associated with lower mortality risks in separate analyses, although significance differed by cohort and outcome.Conclusions: Remaining active pre- and post-diagnosis and becoming active post-diagnosis may be associated with improvements in cancer survival, however, research is needed across diverse cancer populations.","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"81-91"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A scoping review of evidence on routine cervical cancer screening in South Asia: investigating factors affecting adoption and implementation. 南亚常规宫颈癌筛查证据范围审查：调查影响采用和实施的因素。

IF 2.2 4区医学

Cancer Causes & Control Pub Date : 2025-01-01 Epub Date: 2024-10-07 DOI: 10.1007/s10552-024-01923-y

Priyobrat Rajkhowa, Mebin Mathew, Razeena Fadra, Soumyajit Saha, K Rakshitha, Prakash Narayanan, Helmut Brand

{"title":"A scoping review of evidence on routine cervical cancer screening in South Asia: investigating factors affecting adoption and implementation.","authors":"Priyobrat Rajkhowa, Mebin Mathew, Razeena Fadra, Soumyajit Saha, K Rakshitha, Prakash Narayanan, Helmut Brand","doi":"10.1007/s10552-024-01923-y","DOIUrl":"10.1007/s10552-024-01923-y","url":null,"abstract":"NEED: Cervical cancer is a major global public health issue, particularly affecting low and middle-income countries, distinctly in the South Asian region. This geographical region lacks a well-organized routine cervical screening program. Consequently, this scoping review aimed to investigate the evidence on factors influencing the adoption and implementation of routine cervical cancer screening in South Asia.Methods: Adopting the \"Arksey and O'Malley and Levac et al.\" methodology, databases such as PubMed, CINAHL, Web of Science, and Scopus were scrutinized in the pursuit of relevant studies. Subsequently, the collected data were synthesized by adopting the Consolidated Framework for Implementation Research (CFIR) model.Results: A total of 837 records were initially identified and screened for eligibility, including 55 studies. The successful adoption and implementation of cervical cancer screening in South Asia encounter numerous obstacles within the health system, including the absence of a comprehensive program protocol for screening, inadequate health infrastructure, and the presence of multiple sociocultural factors, such as social stigma, low levels of education, and concerns related to modesty.Conclusion: To optimize adoption and implementation, it is imperative to construct a customized policy framework that incorporates a risk communication strategy tailored to the specific contexts of these nations. Drawing insights from the experiences of South Asian countries in executing cervical cancer screening programs can inform the formulation of policies for similar healthcare initiatives aimed at facilitating the expansion of HPV vaccination efforts.","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"67-79"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11761498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology of prostate cancer in Nigeria: a mixed methods systematic review. 尼日利亚前列腺癌流行病学：混合方法系统综述。

IF 2.2 4区医学

Cancer Causes & Control Pub Date : 2025-01-01 Epub Date: 2024-09-22 DOI: 10.1007/s10552-024-01917-w

Chinonyerem O Iheanacho, Okechukwu H Enechukwu

{"title":"Epidemiology of prostate cancer in Nigeria: a mixed methods systematic review.","authors":"Chinonyerem O Iheanacho, Okechukwu H Enechukwu","doi":"10.1007/s10552-024-01917-w","DOIUrl":"10.1007/s10552-024-01917-w","url":null,"abstract":"Purpose: Prostate cancer (PCa) is an increasing burden in Sub-Saharan Africa. This systematic review examined the incidence, prevalence, clinical characteristics and outcomes of PCa in Nigeria.Methods: This review followed the standard Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Peer-reviewed observational studies that focused on epidemiology of PCa in Nigeria, published between 1990 and 2023 and written in English were eligible. Combination of keywords was used to search PubMed, Scopus, Google scholar, AJOL and web of science databases. A piloted form by the Cochrane Public Health Group Data Extraction and Assessment Template was used to extract data from retrieved studies. Quality assessment of included studies was performed using the Newcastle-Ottawa scale for observational studies.Results: Of the 1898 articles retrieved, 21 met the inclusion criteria. All included studies showed good quality. Mean age for PCa ranged from 55 to 71 years, with a higher prevalence occurring within 60-69 years. A 7.7 fold increase in PCa incidence was reported for the years 1997-2006, while an average annual increase in incidence rate of 11.95% was observed from 2009 to 2013. Hospital-based prevalence of 14%-46.4% was observed for clinically active PCa. Patients presented for diagnosis with high Gleason scores and advanced PCa. High mortality (15.6%-64.0%) occurred between 6 months and 3 years of diagnosis.Conclusion: Findings suggest rising incidence and high prevalence of PCa in Nigeria. Advanced PCa was most common at diagnosis and mortality was high. There is need for improved strategies and policies for early detection of PCa in Nigeria.","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating the coverage of the Arkansas All-Payer Claims Database for examining health disparities related to persistent poverty areas in colorectal cancer patients. 调查阿肯色州全付费者索赔数据库的覆盖范围，以研究结直肠癌患者中与持续贫困地区有关的健康差异。

IF 2.2 4区医学

Cancer Causes & Control Pub Date : 2025-01-01 Epub Date: 2024-09-22 DOI: 10.1007/s10552-024-01918-9

Chenghui Li, Cheng Peng, Peter DelNero, Jonathan Laryea, Daniela Ramirez Aguilar, Güneş Koru, Yong-Moon Mark Park, Mahima Saini, Mario Schootman

{"title":"Investigating the coverage of the Arkansas All-Payer Claims Database for examining health disparities related to persistent poverty areas in colorectal cancer patients.","authors":"Chenghui Li, Cheng Peng, Peter DelNero, Jonathan Laryea, Daniela Ramirez Aguilar, Güneş Koru, Yong-Moon Mark Park, Mahima Saini, Mario Schootman","doi":"10.1007/s10552-024-01918-9","DOIUrl":"10.1007/s10552-024-01918-9","url":null,"abstract":"Purpose: We aimed to (1) determine the extent of coverage of colorectal cancer patients in Arkansas All-Payer Claims Database (APCD), (2) assess coverage difference between persistent poverty and other areas, and (3) identify patient, tumor, and area factors associated with inclusion in APCD.Methods: Data were from 2018 to 2020 Arkansas APCD linked with 2019 Arkansas Central Cancer Registry (ACCR). We constructed four cohorts to assess APCD's coverage of CRC patients: (Cohort 1) ≥ 1 day of medical coverage in APCD in 2019; (Cohort 2) APCD coverage in the diagnosis month; continuous APCD coverage in the 30; Year around diagnosis (six months before to five months after diagnosis month) (Cohort 3); or until death within six months (Cohort 4). We compared proportions in the cohorts by area persistent poverty designation. Logistic regressions identified factors associated with inclusion in APCD cohorts.Patient selection: CRC patients diagnosed in 2019 from ACCR, excluding in situ disease.Results: Of the 1,510 CRC patients diagnosed in 2019, 83% had ≥ 1 day of medical coverage in 2019 APCD (Cohort1), 81% had coverage in the diagnosis month (Cohort 2), and 63% had continuous coverage in the year around diagnosis (Cohort 3). Additionally, 11% died within six months but had continuous coverage until death (Cohort 4, 74%). No coverage difference was found between persist poverty and other areas. Age and primary payer type at diagnosis were the main predictors of inclusion in APCD.Conclusion: Arkansas APCD had high coverage of Arkansas CRC patients. No selection bias by area of persistent poverty designation was present.","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"27-44"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical trial knowledge among cancer survivors in the United States: the role of health information technology. 美国癌症幸存者的临床试验知识：医疗信息技术的作用。

IF 2.2 4区医学

Cancer Causes & Control Pub Date : 2025-01-01 Epub Date: 2024-10-08 DOI: 10.1007/s10552-024-01928-7

Ted O Akhiwu, Comfort Adewunmi, Mariah Bilalaga, Joseph O Atarere, Greeshma Gaddipati, Onyema G Chido-Amajuoyi, Diamond K Eziuche, Henry Onyeaka, Hermioni L Amonoo

{"title":"Clinical trial knowledge among cancer survivors in the United States: the role of health information technology.","authors":"Ted O Akhiwu, Comfort Adewunmi, Mariah Bilalaga, Joseph O Atarere, Greeshma Gaddipati, Onyema G Chido-Amajuoyi, Diamond K Eziuche, Henry Onyeaka, Hermioni L Amonoo","doi":"10.1007/s10552-024-01928-7","DOIUrl":"10.1007/s10552-024-01928-7","url":null,"abstract":"Purpose: Clinical trials are essential to the advancement of cancer care. However, clinical trial knowledge and participation remain critically low among adult patients with cancer. Health information technology (HIT) could play an important role in improving clinical trial knowledge and engagement among cancer survivors.Methods: We used data from 3,794 adults who completed the 2020 Health Information National Trends Survey, 626 (16.2%) of whom were cancer survivors. We examined the prevalence of HIT use in the study population and by cancer history using chi-squared tests. We used multivariable logistic regression models to examine the impact of HIT use on clinical trial knowledge for cancer survivors and respondents with no cancer history, respectively.Results: Approximately 63.8% of cancer survivors reported having some knowledge of clinical trials. Almost half of the cancer survivors used HIT to communicate with doctors (47.1%) and make health appointments (49.4%), 68.0% used HIT to look up health information online and 42.2% used it to check test results. In the adjusted models, the use of HIT in communicating with doctors [OR 2.79; 95% CI (1.41, 5.54)], looking up health information online [OR 2.84; 95% CI (1.04, 7.77)], and checking test results [OR 2.47; 95% CI (1.12, 5.43)] was associated with having some knowledge of clinical trials.Conclusion: HIT use for engaging with the healthcare team and health information gathering is associated with higher clinical trial knowledge in cancer survivors. Given the rapid increase in mobile technology access globally and the increased use of HIT, digital technology can be leveraged to improve clinical trial knowledge and engagement among cancer survivors.","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"93-100"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing a city-wide, community-engaged cancer disparities research agenda. 制定全市范围的、社区参与的癌症差异研究议程。

IF 2.2 4区医学

Cancer Causes & Control Pub Date : 2025-01-01 Epub Date: 2024-09-28 DOI: 10.1007/s10552-024-01919-8

Amy E Leader, Yawei Song, Evelyn T González, Thierry Fortune, Nilsa Graciani, Charnita Zeigler-Johnson, Karen Glanz

{"title":"Developing a city-wide, community-engaged cancer disparities research agenda.","authors":"Amy E Leader, Yawei Song, Evelyn T González, Thierry Fortune, Nilsa Graciani, Charnita Zeigler-Johnson, Karen Glanz","doi":"10.1007/s10552-024-01919-8","DOIUrl":"10.1007/s10552-024-01919-8","url":null,"abstract":"Introduction: In response to high levels of cancer disparities in Philadelphia, PA, three NCI-designated clinical cancer centers formed Philadelphia Communities Conquering Cancer (PC3) to bring stakeholders together and establish infrastructure for future cancer reducing initiatives. The PC3 coalition aimed to develop a prioritized cancer disparities research agenda in order to align cancer center resources and research interests with the concerns of the community about cancer, and to ensure that initiatives were patient- and community-centered.Methods: Agenda development activities culminated in a city-wide cancer disparities conference. The conference, attended by 55 diverse stakeholders, was the venue for small group discussion sessions about cancer concerns related to prevention, early detection, treatment, survivorship, and quality of life. Sessions were guided by a moderator guide and were audiorecorded, transcribed, and analyzed by the PC3 leadership team. Results were reviewed and consensus was achieved with the help of PC3's Stakeholder Advisory Committee.Results: Stakeholders identified four thematic areas as top priorities for cancer disparities research and action in Philadelphia: communication between patients, providers, and caregivers; education that reaches patients and community members with tailored and targeted information; navigation that assists people in finding and accessing the right cancer screening or treatment option for them; and representation that diversifies the workforce in clinics, cancer centers, and research offices.Conclusion: A community-informed, prioritized research agenda provides a road map for the three cancer centers to collaborate on future initiatives that are important to patients and stakeholders, to ultimately reduce the burden of cancer for all Philadelphians.","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":"45-50"},"PeriodicalIF":2.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11762217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A narrative review of sleep and breast cancer: from epidemiology to mechanisms. 睡眠与乳腺癌的叙述性回顾：从流行病学到机制。

IF 2.2 4区医学

Cancer Causes & Control Pub Date : 2024-12-28 DOI: 10.1007/s10552-024-01951-8

Bao Zhang, Mengsha Tang, Xiude Li

引用次数: 0

Statin use after cancer diagnosis and survival among patients with cancer. 他汀类药物在癌症诊断后的使用和癌症患者的生存率。

IF 2.2 4区医学

Cancer Causes & Control Pub Date : 2024-12-25 DOI: 10.1007/s10552-024-01939-4

Hanbing Guo, Kathleen E Malone, Susan R Heckbert, Christopher I Li

{"title":"Statin use after cancer diagnosis and survival among patients with cancer.","authors":"Hanbing Guo, Kathleen E Malone, Susan R Heckbert, Christopher I Li","doi":"10.1007/s10552-024-01939-4","DOIUrl":"https://doi.org/10.1007/s10552-024-01939-4","url":null,"abstract":"Purpose: The association between statin use and cancer survival has been investigated in previous studies with conflicting findings. This study aimed to assess the association between statin use following cancer diagnosis and survival in six common cancers using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database.Methods: Individuals aged ≥ 66 years diagnosed with prostate cancer, colorectal cancer, lung cancer, bladder cancer, pancreatic cancer, or non-Hodgkin lymphoma (NHL) from 2008 through 2017 were identified. Statin use was defined as two or more statin prescription fills after cancer diagnosis. Time-dependent Cox proportional hazard regression models were used to estimate the association between statin use and cancer-specific mortality for each cancer.Results: This study included 34,618 patients with prostate cancer (median follow-up 4.0 years), 20,579 with colorectal cancer (2.9 years), 20,133 with lung cancer (1.7 years), 6,163 with bladder cancer (2.1 years), 4,538 with pancreatic cancer (0.8 years), and 3,270 with NHL (2.9 years). Statin use post-diagnosis was associated with a reduced risk of cancer-specific mortality in lung cancer (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.74-0.88) and pancreatic cancer (HR, 0.72; 95% CI, 0.59-0.87). The association was not statistically significant for prostate cancer, colorectal cancer, bladder cancer, or NHL. A dose-response relationship by duration of statin use was observed in lung cancer and pancreatic cancer.Conclusion: Statin use after cancer diagnosis appears associated with improved survival in lung cancer and pancreatic cancer. Clinical trials of statin therapy in lung and pancreatic cancer patients are warranted to confirm these findings.","PeriodicalId":9432,"journal":{"name":"Cancer Causes & Control","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142884970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0